"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Adriblastin- Adriblastin
- Adriblastine
- Adriblastina
- Adriablastine
- Adriablastin
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 8 | 21 | 29 |
| 1995 | 7 | 19 | 26 |
| 1996 | 9 | 21 | 30 |
| 1997 | 5 | 17 | 22 |
| 1998 | 4 | 19 | 23 |
| 1999 | 9 | 16 | 25 |
| 2000 | 10 | 25 | 35 |
| 2001 | 12 | 29 | 41 |
| 2002 | 13 | 34 | 47 |
| 2003 | 16 | 25 | 41 |
| 2004 | 14 | 29 | 43 |
| 2005 | 10 | 34 | 44 |
| 2006 | 11 | 32 | 43 |
| 2007 | 8 | 25 | 33 |
| 2008 | 10 | 41 | 51 |
| 2009 | 12 | 36 | 48 |
| 2010 | 11 | 41 | 52 |
| 2011 | 6 | 35 | 41 |
| 2012 | 8 | 27 | 35 |
| 2013 | 7 | 39 | 46 |
| 2014 | 6 | 44 | 50 |
| 2015 | 10 | 45 | 55 |
| 2016 | 14 | 26 | 40 |
| 2017 | 10 | 31 | 41 |
| 2018 | 6 | 38 | 44 |
| 2019 | 10 | 22 | 32 |
| 2020 | 7 | 29 | 36 |
| 2021 | 5 | 24 | 29 |
| 2022 | 1 | 20 | 21 |
| 2023 | 3 | 20 | 23 |
| 2024 | 6 | 12 | 18 |
To return to the timeline,
click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas. Neuro Oncol. 2024 Nov 04; 26(11):2044-2060.
-
Doxorubicin, Paclitaxel, and Cisplatin (ATP) for Relapsed/Refractory Germ Cell Tumors. Clin Genitourin Cancer. 2024 Dec; 22(6):102242.
-
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. N Engl J Med. 2024 Oct 17; 391(15):1379-1389.
-
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun. 2024 Oct 01; 4(10):2823-2834.
-
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia. 2024 Dec; 38(12):2717-2721.
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
-
T-Cell-Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic Features. Arch Pathol Lab Med. 2024 Aug 01; 148(8):914-920.
-
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study. Lancet Haematol. 2024 Sep; 11(9):e671-e681.
-
Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen. Pediatr Blood Cancer. 2024 Aug; 71(8):e31091.
-
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv. 2024 05 28; 8(10):2342-2350.